{"id":"W4387735431","doi":"10.1056/nejmoa2303974","title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Randomization; Internal medicine; Urology; Placebo; Oncology; Metastasis; Prostate-specific antigen; Combination therapy; Confidence interval; Randomized controlled trial; Surgery; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006473492,0.0001567127,0.0005330963,0.0004085911,0.00002367514,0.000006849391,0.0000947572,0.00004765226,0.0001105797],"category_scores_gemma":[0.0002409116,0.00007545181,0.00005193056,0.0005739226,0.0001108073,0.00006219631,0.0000220558,0.0004400608,0.000003932194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000158865,"about_ca_system_score_gemma":0.0005673821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002386537,"about_ca_topic_score_gemma":0.0001512911,"domain_scores_codex":[0.9985083,0.00003986782,0.0004406776,0.000149771,0.000536542,0.0003248521],"domain_scores_gemma":[0.9989984,0.0001451486,0.0001729916,0.0001301609,0.000211878,0.0003414219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01288296,0.000177805,0.5438302,0.0002299655,0.0004251964,0.002268155,0.003514427,0.00002370925,0.06607363,0.00001247102,0.01076548,0.359796],"study_design_scores_gemma":[0.4230884,0.01306858,0.4854866,0.00707511,0.0006430095,0.001155596,0.001491379,0.0003858317,0.02366501,0.0006383365,0.04283359,0.0004685009],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9501423,0.003806897,0.000009698561,0.04514493,0.0003199195,0.0003169354,0.000004670612,0.00002085217,0.0002337626],"genre_scores_gemma":[0.988319,0.006947136,0.000196066,0.000325148,0.001231046,0.00001402455,0.00001791841,0.00002575394,0.002923945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4102055,"threshold_uncertainty_score":0.3076836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02806320405098852,"score_gpt":0.3483904114940708,"score_spread":0.3203272074430823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}